Administración upstream de inhibidores de la glucoproteína IIb/IIIa en el síndrome coronario agudo sin elevación del segmento ST: la estrategia TACTICS

2007, Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine, Circulation, 116, 803, 10.1161/CIRCULATIONAHA.107.185752 Task, 2007, Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology, Eur Heart J, 28, 1598, 10.1093/eurheartj/ehm161 Worner, 2004, Concepto, clínica, diagnóstico y esquema terapéutico general del síndrome coronario agudo sin elevación del segmento ST, 77 Antman, 2000, The TIMI Risk Score for Unstable Angina/Non-ST Elevation MI: A Method for Prognostication and Therapeutic Decision Making, JAMA, 284, 835, 10.1001/jama.284.7.835 Fox, 2006, Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE), BMJ, 333, 1091, 10.1136/bmj.38985.646481.55 Cannon, 2001, Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban, N Engl J Med, 344, 1879, 10.1056/NEJM200106213442501 Wijns, 2010, Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), Eur Heart J, 31, 2501, 10.1093/eurheartj/ehq277 Bonz, 2002, effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial), J Am Coll Cardiol, 40, 662, 10.1016/S0735-1097(02)02014-4 Gurbel, 2005, Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets: Results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) Study, Circulation, 111, 1153, 10.1161/01.CIR.0000157138.02645.11 Kastrati, 2006, Abciximab in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment: The ISAR-REACT 2 Randomized Trial, JAMA, 295, 1531, 10.1001/jama.295.13.joc60034 Phillips, 1988, The platelet membrane glycoprotein IIb-IIIa complex, Blood, 71, 831, 10.1182/blood.V71.4.831.831 Wiviott, 2007, Prasugrel versus clopidogrel in patients with acute coronary syndromes, N Engl J Med, 357, 2001, 10.1056/NEJMoa0706482 Wallentin, 2009, Ticagrelor versus clopidogrel in patients with acute coronary syndromes, N Engl J Med, 361, 1045, 10.1056/NEJMoa0904327 O’Donoghue, 2009, J Am Coll Cardiol, 54, 678, 10.1016/j.jacc.2009.05.025 Stone, 2006, Bivalirudin for patients with acute coronary syndromes, N Engl J Med, 355, 2203, 10.1056/NEJMoa062437 Cannon, 2001, J Am Coll Cardiol, 38, 2114, 10.1016/S0735-1097(01)01702-8 Rao, 1988, Thrombolysis in myocardial infarction (TIMI) trial--Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase, J Am Coll Cardiol, 11, 1, 10.1016/0735-1097(88)90158-1 Díaz, 2010, Registro Español de Hemodinámica y Cardiología Intervencionista. XIX Informe Oficial de la Sección de Hemodinámica y Cardiología Intervencionista de la Sociedad Española de Cardiología (1990–2009), Rev Esp Cardiol, 63, 1304, 10.1016/S0300-8932(10)70300-6 2006, Comparison of fondaparinux and enoxaparin in acute coronary syndromes, N Engl J Med, 354, 1464, 10.1056/NEJMoa055443 Alexander, 2005, The CRUSADE investigators. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes, JAMA, 294, 3108, 10.1001/jama.294.24.3108 De Carlo, 2009, Effectiveness of the transradial approach to reduce bleedings in patients undergoing urgent coronary angioplasty with GPIIb/IIIa inhibitors for acute coronary syndromes, Cathet Cardiovasc Intervent, 74, 408, 10.1002/ccd.22008 Jolly, 2009, Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: A systematic review and meta-analysis of randomized trials, Am Heart J, 157, 132, 10.1016/j.ahj.2008.08.023 Stone, 2007, Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: The ACUITY Timing Trial, JAMA., 297, 591, 10.1001/jama.297.6.591 Giugliano, 2009, Early versus delayed, provisional eptifibatide in acute coronary syndromes, N Engl J Med, 360, 2176, 10.1056/NEJMoa0901316 Royal Collage of Physicians. The National Clinical Guideline Centre. Unstable Angina and NSTEMI: the early management of unstable angina and non-ST-segmentelevation myocardial infarction [publicadas 24 Mar 2010]. Disponible en: http://guidance.nice.org.uk/CG94/NICEGuidance/pdf/English. Bolognese, 2006, Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: The EVEREST Trial, J Am Coll Cardiol, 47, 522, 10.1016/j.jacc.2005.11.012 Van’t Hof, 2003, A comparison of two invasive strategies in patients with non-ST elevation acute coronary syndromes: results of the Early or Late Intervention in unStable Angina (ELISA) pilot study, Eur Heart J, 24, 1401, 10.1016/S0195-668X(03)00259-8 Roffi, 2002, Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy, Eur Heart J, 23, 1441, 10.1053/euhj.2002.3160 1998, Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction, N Engl J Med, 338, 1488, 10.1056/NEJM199805213382102 1998, A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina, N Engl J Med, 338, 1498, 10.1056/NEJM199805213382103 1998, International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina, Circulation, 97, 2386, 10.1161/01.CIR.97.24.2386 2002, Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes, Circulation, 105, 316, 10.1161/hc0302.102573 1998, Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes, N Engl J Med, 339, 436, 10.1056/NEJM199808133390704 2001, Lancet, 357, 1915, 10.1016/S0140-6736(00)05060-1 Roffi, 2001, Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-STsegment-elevation acute coronary syndromes, Circulation, 104, 2767, 10.1161/hc4801.100029 Mehta, 2005, Routine vs selective invasive strategies in patients with acute coronary syndromes: A collaborative meta-analysis of randomized trials, JAMA, 293, 2908, 10.1001/jama.293.23.2908 De Winter, 2005, Early invasive versus selectively invasive management for acute coronary syndromes, N Engl J Med, 353, 1095, 10.1056/NEJMoa044259 Akkerhuis, 2002, Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different?, Circulation, 105, 554, 10.1161/hc0502.104278 Morrow, 2004, Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS), J Am Coll Cardiol, 94, 774, 10.1016/j.amjcard.2004.05.065 Boersma, 2002, Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials, Lancet, 359, 189, 10.1016/S0140-6736(02)07442-1 Danzi, 2006, Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb/IIIa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention, Am J Cardiol, 97, 489, 10.1016/j.amjcard.2005.09.080 Schneider, 2005, Variation in the ability of glycoprotein IIb-IIIa antagonists to exert and maintain their inhibitory effects on the binding of fibrinogen, J Cardiovasc Pharmacol, 46, 41, 10.1097/01.fjc.0000162770.83324.17 Schneider, 2006, Increased ability of tirofiban to maintain its inhibitory effects on the binding of fibrinogen to platelets in blood from patients with and without diabetes mellitus, Coron Artery Dis, 17, 57, 10.1097/00019501-200602000-00010 Peterson, 2003, Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction: Observations from the National Registry of Myocardial Infarction 4, J Am Coll Cardiol, 42, 45, 10.1016/S0735-1097(03)00514-X Manoukian, 2007, Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes. An analysis from the ACUITY trial, J Am Coll Cardiol, 49, 1362, 10.1016/j.jacc.2007.02.027 Fox, 2007, Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non-ST-segment elevation acute coronary syndromes, Ann Intern Med, 147, 304, 10.7326/0003-4819-147-5-200709040-00005